- #150: Demenz-Qualitätsregister: Kartierung von Registern zur Verbesserung der Qualität und Leistungserbringung
- #149: Modelle zur Prävention und Versorgung psychischer Erkrankungen bei Kindern und Jugendlichen
- #148: Modelle zur Prävention und Versorgung peripartaler psychischer Erkrankungen
- #147: Unterstützung von Kindern mit psychisch erkrankten Eltern in Tirol: Zusammenfassende Ergebnisse des Village Projekts (abgeschlossen/nicht veröffentlicht)
- #146: CAR-T Zelltherapien (Axicabtagen-Ciloleucel/Yescarta®) oder Tisagenlecleucel/Kymriah®): Kontrastierung der Zulassungsstudien mit Daten aus Versorgungsstudien
- #145: Risikobasiertes Brustkrebs-Screening in Österreich: Systematische Analyse der Vorhersagemodelle zur Erfassung des individuellen Brustkrebsrisikos, deren Nutzen und Anwendbarkeit im Brustkrebs-Screening-Programm
- #144: Osteopathie: Wirksamkeit und Sicherheit bei Schmerzen des Bewegungs- und Stützapparates und Übersicht zu Ausbildungs- und Qualitätserfordernissen
- #143: Telemedizinische Diabetesversorgung in Österreich: Eine systematische Analyse von Evaluierungsmethoden
- #135b/Update 2022: Long Covid – Versorgungspfade und Versorgungsstrukturen
- DSD 134: Laparoskopische Reflux-Management-Verfahren für den unteren Ösophagussphinkter (UÖS) bei Patient*innen mit GERD
- DSD 133: Chemosaturation mit perkutaner Leberperfusion für Patient*innen mit Leberkrebs
- DSD 132: His-bundle-pacing zur Stimulation des kardialen Reizleitungssystems
- DSD 131: Mikrowellenablation bei Lebertumoren
- DSD 130: Lebervenen- und Pfortaderembolisation vor einer Major-Leberresektion
- Update / DSD 121/Update 2022: Perkutane transvaskuläre Implantation eines Stents zur Verengung des Koronarsinus
- Update / DSD 109/Update 2022: Subcutaneous implantable cardioverter-defibrillator (S-ICD)
- Update / DSD 100/Update 2022: Stimulation der oberen Atemwege bei mittelschwerer bis schwerer Schlafapnoe
- Update / DSD 74/Update 2022: Zytoreduktive Chirurgie und hypertherme intraperitoneale Chemotherapie bei sekundärer Peritonealkarzinose (Master Arbeit / nicht im Auftrag des BMSGPK erstellt)
- Update / DSD 64/Update 2022: Perkutane koronare Interventionen (PCI) bei chronischen Komplettverschlüssen (CTO)
- #116/Update: Durvalumab (Imfinzi®) for Biliary tract cancer
- #115/Update: Trastuzumab deruxtecan (Enhertu®) for Gastric or gastroesophageal junction (GEJ) adenocarcinoma
- #114/Update: Lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
- #113/Update: Cemiplimab (Libtayo®) as monotherapy for the treatment of recurrent or metastatic cervical cancer
- #112/Update: Zanubrutinib (Brukinsa®) as monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL)
- #111/Update: Axicabtagene ciloleucel (Yescarta®) for the treatment of patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)
- #110/Update: Zanubrutinib (Brukinsa®) as monotherapy for the treatment of marginal zone lymphoma (MZL)
- #109/2. Update: Loncastuximab tesirine (Zynlonta®) as monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)
- #108/Update: Selpercatinib (Retsevmo®) as monotherapy for the treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC)
- #107/Update: Teclistamab (Tecvayli®) as monotherapy for the treatment of patients with relapsed and refractory multiple myeloma (MM) who have received at least three prior therapies
- #106/Update: Autologous anti-CD19-transduced CD3+ cells (Tecartus®) for the treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL)
- #105/Update: Relatlimab/nivolumab (Opdualag®) for the first line treatment of advanced melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%
- #104/Update: Olaparib (Lynparza®) as monotherapy or in combination with endocrine therapy for the adjuvant treatment of patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer
- #103/Update: Ibrutinib (Imbruvica®) in combination with venetoclax for the treatment of previously untreated chronic lymphocytic leukaemia (CLL)
- #102/Update: Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of unresectable or metastatic HER2 positive breast cancer
- #101/Update: Asciminib (Scemblix®) for the treatment of Philadelphia chromosome?positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase (CP)
- #100/Update: Melphalan flufenamide (Pepaxti®) with dexamethasone for the treatment of multiple myeloma (MM)
- #99/Update: Pembrolizumab (Keytruda) as monotherapy for the adjuvant treatment of stage IIb IIc III melanoma
- #98/Update: Selinexor (Nexpovio®) in and dexamethasone for the treatment of multiple myeloma (MM)
- #97/Update: Axicabtagene ciloleucel (Yescarta®) Follicular lymphoma
- #96/Update: Atezolizumab (Tecentriq®) NSCLC
- #95/Update: Selpercatinib (Retsevmo®) NSCLC
- #94/Update: Pembrolizumab (Keytruda®) TNBC
- #93/Update: Capmatinib (Tabrecta®) NSCLC
- #92/Update: Mosunetuzumab (Lunsumio®) Follicular lymphoma
- #91/Update: Pembrolizumab (Keytruda®) in combination with chemotherapy with or without bevacizumab for cervical cancer
- #90/Update: Pembrolizumab (Keytruda®) as monotherapy in adults with colorectal cancer
- #89/Update: Polatuzumab vedotin (Polivy®) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of B-cell lymphoma (DLBCL)
- #88/Update: Tisagenlecleucel (Kymriah®) for the treatment of follicular lymphoma (FL) after two or more lines of systemic therapy
- #87/Update: Cabozantinib (Cabometyx®) as monotherapy for the treatment of thyroid carcinoma (DTC)
- #86/Update: Ciltacabtagene autoleucel (Carvykti®) for the treatment of multiple myeloma (MM)
- #85/2. Update: Enfortumab vedotin (Padcev®) as monotherapy for the treatment of patients with locally advanced or metastatic urothelial cancer
- #84/Update: Abemaciclib (Verzenios®) bei early breast cancer
- #83/Update: Nivolumab (Opdivo®) + chemotherapy bei OSCC
- #82/Update: Ipilimumab (Yervoy®) + Nivolumab (Opdivo®) bei OSCC
- #81/Update: Nivolumab (Opdivo®) bei MIUC
- #80/2. Update: Relugolix (Orgovyx®) bei Prostate Cancer
- #79/2. Update: Tebentafusp (Kimmtrak®) bei Uveal melanoma
- #78/Update: Avapritinib (Ayvakyt®) for the treatment of advanced systemic mastocytosis (AdvSM)
- #77/Update: Lisocabtagene maraleucel (Breyanzi) for the treatment of relapsed or refractory DLBCL
- #76/Update: Tegafur/gimeracil/oteracil (Teysuno®) for the treatment of metastatic colorectal cancer
- #75/Update: Lorlatinib (Lorviqua®) as monotherapy for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)
- #74/Update: Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of renal cell carcinoma (RCC)
- #73/Update: Tepotinib (Tepmetko®) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC)
- #72: Enfortumab vedotin (Padcev®) as monotherapy for the treatment of patients with locally advanced or metastatic urothelial cancer
- #71/Update: Sotorasib (Lumykras®): Sotorasib (Lumykras®) as monotherapy for the treatment of advanced NSCLC with KRAS G12C mutation
- #70/Update: Sacituzumab govitecan (Trodelvy) as monotherapy for the treatment of patients with unresectable or metastatic triple-negative breast cancer (mTNBC)
- #69/Update: Amivantamab (Rybrevant) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC)
- #68/Update: Pembrolizumab (Keytruda) in combination with Lenvatinib (Kisplyx) for the treatment of advanced or recurrent endometrial carcinoma (EC)
- #67/Update: Pembrolizumab (Keytruda) in combination with Lenvatinib (Kisplyx) for the firstline treatment of advanced renal cell carcinoma (RCC)
- #66: Degarelix (Firmagon®) as a neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone-dependent prostate cancer
- #65: Degarelix (Firmagon®) as a neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone-dependent prostate cancer